First_author;Last_author;Journal;Publication_year;Gene_number;List up;Technology;Cancer;Comments;Title;Doi
R Cabrita;G Jönsson;Nature;2020;9;CD79B, CD1D, CCR6, LAT, SKAP1, CETP, EIFA1Y, RBP5, PTGDS;SAM analysis and scRNA-seq;Melanoma; identify genes overexpressed in CD8+CD20+ versus CD8+ groups and subtracted the genes overexpressed in CD8+ versus double-negative groups.Two groups, which were independent of tumour core and patient, were clearly discerned on the basis of Ki67 expression.;"Tertiary lymphoid structures improve immunotherapy and survival in melanoma
";https://doi.org/10.1038/s41586-019-1914-8
D Coppola;J J Mulé;The American Journal of Pathology;2011;12;CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, CXCL13;mRNAMicroarray;Colorectal;"12-chemokine gene signature ; Metagene analysis with gene chip technology ; Chemokines are up-regulated in tumors with ectopic lymph node structures.";"Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
";10.1016/j.ajpath.2011.03.007
G Bindea;J Galon;Immunity;2013;1;CXCL13;DNA microarray;Colorectal;only 1 gene;"Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
";http://dx.doi.org/10.1016/j.immuni.2013.10.003
I P.MacFawn;T C Bruno;Cancer Cell;2024;20;ARHGDIB, BIRC3, CD52, CD79A, CORO1A, CXCL9, CYTIP, LCP1, LIMD2, LSP1, LTB, PLEK, POU2AF1, PTPRC, PTPRCAP, RCSD1, SELL, TAGAP, WIPF1, TRBC1;DSP;Ovarian;"By setting a threshold of 2-fold enrichment in the “TLS” enriched DEGs, we produced a 20-gene “TLS-DSP” signature
";;https://doi.org/10.1016/j.ccell.2024.09.007
X Wang;C Sotirou;Nature Communications;2024;30;CD79A, CD79B, TNFRSF13C, BLK, CD22, CD37, MS4A1, NIBAN3, CD19, IKZF3, LINC00926, CXCR5, LTB, SELL, CCL19, POU2AF1, CXCL13, FCRLA, VPREB3, FCMR, AL928768.3, RASGRP2, TCF7, RIPOR2, RAC2, IL16, CCR7, CD52, TCL1A, ATP2A3;"ST Arrays
";Breast; comparing gene expression data from TLS versus lymphocyte compartment as well as TLS versus other non-immune-related compartments;"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications
";https://doi.org/10.1038/s41467-024-54145-w
R Wu;L Chen;Science Advances;2021;50;FDCSP, CR2, CXCL13, LTF, CD52, MS4A1, CCL19, LINC00926, LTB, CORO1A, CD79B, TXNIP, CD19, LIMD2, CD37, ARHGAP45, BLK, TMC8, CCL21, PTPN6, ATP2A3, IGHM, SPIB, TMSB4X, CXCR4, NCF1, CD79A, ARHGAP9, DEF6, EVL, TBC1D10C, RASAL3, INPP5D, RNASET2, RASGRP2, TNFRSF13C, RAC2, CD22, ARHGEF1, AC103591.3, TRAF3IP3, HLA-DQB1, CD53, ARHGAP4, TRBC2, POU2AF1, TRAF5, OGA, FCRL3, HLA-DQA1;Visium Spatial transcriptomics;Liver;;"Comprehensive analysis of spatial architecture in primary liver cancer
";10.1126/sciadv.abg3750
Y Zhang;D chen;Science Advances;2024;83;RPS15A, LTB, RPS11, CCL5, LSP1, CD3D, AKNA, CCL19, TRBC1, RPL18A, CD44, HLA-DPB1, CYBA, 1-Sep, RPS27, TRAC, HLA-DRB1, TBC1D10C, ZAP70, ZFP36L2, HLA-DQA1, CD52, RPL21, JAK3, CD37, SRGN, RASAL3, CD79A, RPS6, CXCR4, LIMD2, ATP2A3, CD79B, RACK1, TSC22D3, RPL13, ARHGAP45, LAPTM5, ACAP1, ARHGAP4, GMFG, LDHB, TRBC2, RPS3, IGFBP7, CD74, HLA-DRA, CIRBP, COL6A2, RPS3A, CCL21, EVL, CD2, RAC2, NOP53, LAT, CORO1A, HLA-E, IL7R, TXNIP, HCST, FXYD5, RASGRP2, RPL34, ARHGDIB, ARHGEF1, HLA-DQB1, ITGB2, DEF6, EMILIN1, RPS9, VWF, LUM, IGHM, KLF2, GSTP1, HSPG2, HLA-DMA, AEBP1, CCDC85B, VSIR, MFAP4, INMT;;;83 gene signature;"SpaTopic: A statistical learning framework for exploring tumor spatial architecture from spatially resolved transcriptomic data
";10.1126/sciadv.adp4942
Y Zhang;D chen;Science Advances;2024;25;CCL19, CD52, TRBC2, CORO1A, LTB, CXCR4, ARHGAP45, CCL21, LIMD2, EVL, ARHGEF1, TBC1D10C, CD37, ATP2A3, TXNIP, HLA-DQB1, CD79B, ARHGAP4, RAC2, RASAL3, DEF6, HLA-DQA1, CD79A, RASGRP2, IGHM;;;25 common ith the 50 gene of the liver;"SpaTopic: A statistical learning framework for exploring tumor spatial architecture from spatially resolved transcriptomic data
";10.1126/sciadv.adp4942
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;
;;;;;;;;;;